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URINARY & KIDNEY DISORDERS
PUR1
HEALTH STATUS OF ELDERLY
DIALYSIS PATIENTS
Boening AJ1, Chapman MM1, Brown RH2, Zager PG2, Meyer KB1
1New England Medical Center, Boston, MA, USA; 2Dialysis 
Clinics, Inc, Albuquerque, NM, USA
OBJECTIVES: The elderly comprise approximately half
of new patients undergoing dialysis, an expensive, lifesav-
ing treatment. We report the health status of 3 elderly age
groups, including novel information about patients 
85
years, hypothesizing that as age increases health status
will decrease. METHODS: This retrospective analysis re-
ports on 6154 patients treated by one dialysis chain
(48.4% male, 61.5% white, 39.1% diabetes as primary
diagnosis). Health status is reported by a single adminis-
tration of the SF-36 between 10/30/90 and 10/30/00. RE-
SULTS: Although not statistically significant at p  .01,
with increasing age, there are trends to lower Physical
Function and Role Physical scores. The Physical Compo-
nent Score shows a statistically significant difference be-
tween groups 1 and 2. Group 3, the very elderly, are not
significantly different from groups 1 or 2. Other scales
show no change. CONCLUSIONS: As hypothesized,
physical health of dialysis patients appears vulnerable to
age. However, other domains of health status remain ro-
bust. The very elderly receiving dialysis maintain their
mental health when compared to patients in the 2 younger
age groups. (See table below.)
PUR2
EVIDENCE OF DISEASE PROGRESSION IN 
ADULT PATIENTS WITH AN OVERACTIVE 
BLADDER (OAB)
Zhou Z1, Barr CE1, Torigoe Y1, Williamson TE1, Shah J2
1Pharmacia, Peapack, NJ, USA; 2Institute of Urology, London, UK
OBJECTIVES. This study examined patterns of transi-
tion of bladder symptoms in adult patients with an over-
active bladder, identified risk factors for such transitions,
and assessed the impact of symptom transition on patient
outcomes of depression and accidental falls. METHODS:
This study was a retrospective, population based cohort
study using the General Practice Research Database
(GPRD) containing medical records from 550 of 686
general practices in the UK. The baseline period included
the year in which a patient’s first OAB symptom or diag-
nosis record occurred and the following year. The follow-
up period was six years. A total of 9,706 patients, aged
40 years or older met the criteria. Transition rates from
frequency/urgency to incontinence, and from urge incon-
tinence to frequency/urgency were calculated. Logistic re-
gression was used to examine the impact of risk factors
on symptom transition, and its effect on a patient’s risk
of depression and accidental fall. RESULTS: Of female
patients with OAB, 23.4% had “frequency/urgency” at
baseline and developed “incontinence” in the follow-up
period—potentially reflecting progression of the condi-
tion. Factors associated with progression of OAB in-
cluded older patients (70 to 90 years), female gender, ur-
gency, accidental falls, multiple sclerosis, and epilepsy.
Controlling for these factors, patients with progression
showed an increased risk of depression and accidental
fall compared to patients who had no change in symp-
toms (adjusted odds ratios 1.44 and 1.35, respectively;
p  0.0001 for both). CONCLUSION: OAB appears to
be a progressive disease. A significant proportion of pa-
tients progressed from “dry” to “wet” symptoms. This
may imply that some patients with OAB, if left un-
treated, will develop progression of OAB over time. The
risks of depression and accidental falls were significantly
increased in those patients whose OAB condition wors-
ened. Further research is required to determine whether
treatment can prevent, reduce, or delay the progression
of OAB syndrome.
PUR3
PERSISTENCE OF THERAPY WITH DRUGS FOR 
OVERACTIVE BLADDER
Zhou Z, Barr CE, Torigoe Y, Williamson TE
Pharmacia, Peapack, NJ, USA
OBJECTIVE: This study evaluates the real world persis-
tency of therapy for overactive bladder (OAB), compar-
ing tolterodine, oxybutynin and flavoxate head-to-head
in a large sample extracted from a US drug claim data-
base. Clinical trials have shown tolterodine has equal ef-
ficacy to oxybutynin in reduction of OAB symptoms and
Table for PUR1 Mean SF-36 SCORE (SD)
1652 1
Physical
Function
Role
Physical Bodily Pain
General
Health Vitality
Social
Function
Role
Emotional
Mental
Health
Physical
Component
Score*
Mental
Component
Score
Group 1
65–74
36.9 (27.8)
n  3687
29.3 (37.9)
n  3609
58.5 (29.0)
n  3674
43.2 (20.1)
n  3587
42.7 (22.8)
n  3635
62.8 (28.8)
n  3687
55.7 (43.6)
n  3577
69.2 (20.0)
n  3621
31.8 (10.1)
n  3445
48.3 (11.3)
n  3445
Group 2
75–84
32.4 (26.2)
n  2117
26.8 (36.4)
n  2059
58.1 (28.4)
n  2111
44.2 (20.0)
n  2073
40.8 (22.4)
n  2098
61.3 (30.0)
n  2119
54.2 (43.9)
n  2038
69.5 (20.1)
n  2089
30.9 (9.4)
n  1957
48.4 (11.6)
n  1957
Group 3

85
30.0 (27.1)
n  267
26.8 (37.5)
n  257
58.7 (58.7)
n  266
46.8 (21.1)
n  254
42.1 (23.0)
n  261
63.5 (30.1)
n  267
53.6 (44.5)
n  257
71.5 (19.1)
n  258
30.7 (10.0)
n  244
49.5 (11.0)
n  244
*  p  .01
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a significantly better side-effect profile. METHOD: A
longitudinal study was conducted using drug claims from
PCS Health Systems. The study cohort consists of 4602
“naïve tolterodine users”, 7291 “naïve oxybutynin us-
ers” and 2127 “naive flavoxate users.” Survival analysis
was used to estimate the “persistence rate”—defined as
the proportion of patients who are still on a drug treat-
ment during or after a defined period of continuous treat-
ment for the drug. A Cox-regression model was used to
assess the net effect of using tolterodine or oxybutynin on
the persistence of drug therapy controlling for differences
in the patients’ demographics, comorbid conditions, and
other factors. RESULTS: The persistence on tolterodine
was 30% higher than that on oxybutynin on continuous
treatment periods of 31–60 days, and 90% higher for
301–360 days of therapy. The persistence on tolterodine
was 430% higher than that on flavoxate for treatment
periods of 30–60 days and 340% higher for 301–360
days of therapy. The average length of continuous treat-
ment for naive tolterodine users was the longest of the
three drugs: 143(3.9) days compared to 91(2.6) days for
oxybutynin and 41(4.6) days for flavoxate. The adjusted
odds-ratio of terminating drug treatment for tolterodine
vs. oxybutynin users was 0.66 (p  0.001). CONCLU-
SIONS: Patients using tolterodine were significantly more
likely to continue their treatment than those choosing
other OAB drugs. The better persistence for tolterodine
users should result in longer symptom relief for patients,
particularly for those who are in need of long-term treat-
ment but are distressed by side effects.
PUR4
ANALYSIS OF COMORBIDITY IN OVERACTIVE 
BLADDER AND URINARY INCONTINENCE IN A 
MANAGED CARE ORGANIZATION
Juzba M, White TJ, Chang EY
Prescription Solutions, Costa Mesa, CA, USA
OBJECTIVE: The primary objectives of this study are to
examine the costs of overactive bladder and urinary in-
continence (OAB/UI) and evaluate for the presence of de-
pression and falls and fractures as comorbid conditions
from a managed care perspective. METHOD: Retrospec-
tive computerized claims records from a managed care
organization were analyzed. Patients were included if
they had an ICD-9 code consistent with OAB or UI, were
under treatment and were continuously eligible between
1/1/99 and 12/31/99 (N  445). Randomly sampled con-
trol patients from the general membership were matched
on age and gender with the OAB/UI group at a ratio of
5:1 (N  2,220). Diagnoses of depression and of falls,
fractures and contusions were collected and a Charlson
comorbidity index was developed for all study patients.
Depression-related costs and falls & fracture-related
costs included those directly related to treatment. RE-
SULTS: Seventeen (0.77%) of the control patients had a
diagnosis of depression compared to 2.02% of the OAB/UI
patients (P  0.0001). Of the OAB/UI patients, 13.93%
were diagnosed with a fall or fracture compared to 8.11%
of the control patients (P  0.0001). The mean Charlson
score of the OAB/UI group was 0.51 (SD 1.10) compared
to 0.37 (SD 1.00) for the control group (P  0.01). The
mean cost of treating depression was $33 (SD $605) for
the control group and $42 (SD $138) for the OAB/UI
group (P  0.0001). The average cost of treating falls &
fractures was $154 (SD $1,922) for the control group
and $434 (SD $4,946) for the OAB/UI group (P  0.0001).
CONCLUSION: Compared to the general population, pa-
tients with a diagnosis of OAB/UI are significantly more
likely to experience a fall or fracture or experience de-
pression. They also tend to have a significantly higher
burden of comorbidity. The average cost of fall & frac-
ture treatment and treatment of depression is signifi-
cantly higher among OAB/UI patients.
PUR5
THE IMPACT OF PHARMACOTHERAPY ON 
OVERACTIVE BLADDER SYMPTOM 
IMPROVEMENT AND RESOURCE UTILIZATION
Pashos CL1, Grossman M1, Bull S2
1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Alza 
Corporation, Mountain View, CA, USA
OBJECTIVES: To examine the effects of drug treatment
on overactive bladder (OAB) symptom improvement and
resource utilization. METHODS: We conducted an ob-
servational study of 217 OAB patients enrolled by 31
physicians nationwide. One hundred twenty-two patients
have been tracked through 3 months to determine symp-
tom improvement, change(s) in treatment, and resource
utilization. The impact of medication on OAB symptom
improvement was modeled using stepwise logistic regres-
sion adjusting for patient age, sex, symptom duration,
symptom severity, incontinence, frequency of leakage ac-
cidents, and frequency of urinations. RESULTS: Partici-
pants averaged 60.7 years old (S.D.  15.7), 85.2% were
female, and the mean duration of OAB symptoms was
8.1 years. On average, patients experienced 11.0 uri-
nations per day (S.D.  4.7) and 2.2 accidents per day
(S.D.  3.4). Treatment with medication increased the
odds of symptom improvement by four-fold (odds ratio
(O.R.)  4.3, 95% confidence interval (CI) 1.8–9.9). Pa-
tients with incontinence were significantly more likely to
report improvement in symptoms compared with pa-
tients with urinary frequency alone (O.R.  3.2, 95%CI
1.2–8.4). Nineteen of 72 (26%) patients not started on
medication at baseline began medication within the first
3 months, consuming an average of 1.16 office visits per
patient. In contrast, 11 of 50 patients (22%) who were
started on medication at baseline discontinued within the
first 3 months, consuming an average of 0.64 office visits
per patient. Patients staying on medication (39/50, 78%)
consumed on average the fewest office visits per patient
(0.15), while patients who managed symptoms without
medication (53/72, 73%) consumed an average of 0.26
office visits. CONCLUSIONS: Pharmacotherapy signifi-
